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Understanding of antibiotic resistance in Streptococcus
pneumoniae has been hindered by the low frequency
of recombination events in bacteria and thus the
presence of large linked haplotype blocks, which
preclude identification of causative variants. A recent
study combining a large number of genomes of
resistant phenotypes has given an insight into the
evolving resistance to β-lactams, providing the first
large-scale identification of candidate variants
underlying resistance.carried out by the transpeptidase/penicillin-binding do-
main present in all PBPs. Because β-lactams are covalentlyStreptococcus pneumoniae has been causally attributed
to many diseases, such as pneumonia, septicemia and
meningitis. β-Lactam antibiotics such as penicillins and
cephalosporins are the main form of treatment, but anti-
biotic resistance is a frequent problem for which the
underlying mechanism remains elusive. A recent study
by Julian Parkhill and colleagues [1] of more than 3,000
isolates of this pathogen examined which genes (and
mutations therein) are responsible for the evolution of
penicillin resistance. One might wonder why we need to
obtain genome sequences from thousands of isolates for
what might seem a simple question? In fact, the develop-
ment of penicillin resistance in S. pneumoniae is far from
being simple.
Unlike in many other bacterial pathogens, β-lactam re-
sistance in pneumococci is not related to β-lactamase
production; for unknown reasons β-lactamases have not
been detected in S. pneumoniae so far. Instead, the re-
sistance mechanism involves alterations in genes encoding
target enzymes for β-lactam antibiotics, the penicillin-
binding proteins (PBPs; reviewed in [2,3]). PBPs are cru-
cial enzymes acting in the biosynthesis of peptidoglycan
(PG), a major constituent of the bacterial cell wall. TheyCorrespondence: hakenb@rhrk.uni-kl.de
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The PG layer can be visualized as one huge macromol-
ecule surrounding the entire cell; it maintains the shape
of the cell and is required for its osmotic stability.
PG is composed of glycan strands with alternating
N-acetylglucosamine (GlcNAc) and N-acetylmuramic
acid (MurNAc) residues, the latter containing short pep-
tides. Elongation of the glycan strands and crosslinking of
the peptides results in the network-like structure ubiqui-
tously found in bacteria; these two reactions are carried
out by different PBPs. Peptide crosslinking, a transpepti-
dation reaction, is the crucial penicillin-sensitive step
bound through the active-site serine of the PBP, mutations
in β-lactam-resistant strains reduce the protein's affinity
for the antibiotic; that is, the mutated enzymes do not
interact with the inhibitory drug even at higher concentra-
tions, and PG biosynthesis can continue. Identification of
the variants that cause resistance is thus important in de-
fining the mechanism of resistance.
Research into causal variants is confounded by the fol-
lowing issues. First, at least three PBPs are required for
high-level resistance in S. pneumoniae. Second, there are
different mutational pathways that result in a low-affinity
PBP. Third and most importantly, resistant clinical strains
contain mosaic genes in which sections are replaced by
highly altered sequences that differ by approximately 20%
at the DNA level, the result of interspecies gene transfer
followed by recombination events. This means that only a
few of the mutations detected in the PBP genes are related
to resistance [2]. As S. pneumoniae is a naturally trans-
formable species, that is, it takes up DNA easily, so resist-
ance determinants can be transferred easily within the
population via intraspecies gene transfer, giving rise to
new mosaic structures. Last but not least, non-PBP genes
have been shown also to contribute to resistance.
In other words, within the pneumococcal population
there is a highly variable gene pool of mosaic PBP and
non-PBP genes, and each resistant clone may contain atd. The licensee has exclusive rights to distribute this article, in any medium, for
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type. As a consequence, there is a wide range of resistance
profiles, including preferential resistance for a subfamily
of β-lactams such as cephalosporins. One example is the
appearance of high-level cephalosporin-resistant strains in
the USA, the consequence of one single mutation in the
PBP2x gene [4].
Parkhill and colleagues [1] used a series of bioinfor-
matic tools to identify single nucleotide polymorphisms
(SNPs) and indels that are associated with β-lactam re-
sistance. They studied two independent datasets derived
from a collection of β-lactam-sensitive and -resistant S.
pneumoniae samples from Thailand and the USA, two
bacterial populations that have evolved independently
and thus represent a very different spectrum of geno-
types. In the era of genomics, it is extremely important
to use appropriate tools to analyze big datasets, and this
study is a perfect example of how to achieve a high-
resolution genetic analysis from the genomes of more
than 3,000 isolates. The large dataset allowed the nar-
rowing down of large recombinant mosaic blocks to
much smaller loci, enabling the identification of SNPs
that may be causally associated. In total, 301 SNPs
across 51 loci were found to be associated with non-
susceptibility in both pneumococcal populations; these
are preferential candidates for experimental testing. This
included the confirmation of many previously identified
loci and SNPs and 43 novel non-synonymous poly-
morphic changes, documenting the effectiveness of the
method. Parkhill and colleagues [1] also demonstrated
preferential association of the loci with resistance to spe-
cific subfamilies of β-lactams, penicillins or cephalospo-
rins, suggesting that the underlying mechanisms may be
different.
For basic research, the identification of new SNPs is
important for our understanding of the mode of action
of PBPs. But which SNPs should be tested in an experi-
mental setting? Some SNPs might be associated with
genes that are located close to the actual target as a result
of a hitchhiking effect during gene transfer and recombin-
ation events rather than having a role in resistance itself.
Parkhill and colleagues [1] identified a variety of genes be-
sides those encoding PBPs. Among them, the genes mraY
and mraW (encoding transferases in PG biosynthesis), ftsL
(involved in cell division) and clpL (encoding a heat shock
protein and chaperone) are located up- and downstream
of pbp2x. Although clpL has been shown to be associated
with penicillin susceptibility [5], further experimental test-
ing is required to distinguish causative SNPs from hitch-
hiking SNPs by recombination, and the same is true for
recU, located upstream of pbp1a.
Some SNPs might be compensatory mutations to reduce
an adverse effect of primary resistance mutations in what
are, after all, essential enzymes. Testing a mutation for itseffect on resistance is also a difficult matter. Some of the
mutations known to be important confer only a fairly
moderate effect on susceptibility when introduced as a
single mutation in the wild-type background. The ef-
fect of mutation on the activity of the enzymes them-
selves is not well known, and compensatory mutations
may also occur in other genes. This includes compo-
nents of the machinery responsible for PG synthesis
and for cell division apparatus, pathways for which pos-
sible resistant variants were found in this study [1]. Most
PBPs of S. pneumoniae are located at the division
septum and are part of protein complexes required for
division and cell elongation [6]. Because of this complex-
ity, it will be necessary to analyze SNPs that are associated
with both frequent and rare resistance pathways in indi-
vidual lineages. Functional validation of the results will re-
quire extensive work, including the structural resolution
of new variants of the cell wall synthesis and cell division
machinery.
There are important issues of clinical importance.
The SNPs identified here [1] are distributed not only
in vaccine-targeted but also in non-vaccine-targeted line-
ages. The polysaccharide capsule is a major pathogenicity
factor in pneumococci, and antibodies directed against
it represent a major defense mechanism against this
pathogen. Over 93 biochemically distinct capsule types are
known [7], but only a few are common in humans.
Protein-conjugated vaccination against the prevalent 7
and more recently 13 serotypes has been successfully
implemented in many countries, leading to a reduction
in infection, especially among children, with a major ef-
fect on invasive and non-invasive disease [8-10]. The
fact that Chewapreecha et al. [1] now show that the
SNPs are enriched not only in vaccine-targeted but
also non-vaccine-targeted lineages is one potential ex-
planation for why vaccination has not reduced β-lactam
resistance within the population. Thus, some non-vaccine-
targeted lineages containing a high frequency of resistant
alleles can act as both a source and a sink of resistance al-
leles within the population.
Sequence-based detection of SNPs may be useful to
predict penicillin susceptibility in clinical microbiology,
providing rapid diagnostic testing required for optimal
therapy. Moreover, this may pave the way to the devel-
opment of antibiotics that target specific variants and
could address the ever-evolving problem of the spread of
antibiotic resistance.Abbreviations
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